Krystal Biotech’s (KRYS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Krystal Biotech (NASDAQ:KRYS) in a research note published on Thursday,Benzinga reports. They currently have a $361.00 price target on the stock.

Other research analysts have also recently issued reports about the stock. Citigroup upped their price objective on shares of Krystal Biotech from $378.00 to $386.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. TD Cowen upped their target price on shares of Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a research report on Thursday, June 18th. Jefferies Financial Group reissued a “buy” rating and issued a $474.00 target price on shares of Krystal Biotech in a research note on Monday, July 13th. Weiss Ratings downgraded Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, October 9th. Finally, The Goldman Sachs Group initiated coverage on Krystal Biotech in a research report on Thursday, September 24th. They set a “buy” rating and a $441.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Krystal Biotech has an average rating of “Buy” and a consensus price target of $377.20.

Krystal Biotech Stock Performance

Shares of KRYS opened at $316.58 on Thursday. The stock has a market capitalization of $9.37 billion, a price-to-earnings ratio of 39.67 and a beta of 0.50. Krystal Biotech has a 52-week low of $183.03 and a 52-week high of $382.54. The stock’s 50-day simple moving average is $340.41 and its 200 day simple moving average is $323.15.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, August 3rd. The company reported $1.79 earnings per share for the quarter, beating the consensus estimate of $1.70 by $0.09. The firm had revenue of $119.22 million for the quarter, compared to analysts’ expectations of $120.93 million. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. On average, research analysts forecast that Krystal Biotech will post 7.40 earnings per share for the current fiscal year.

Insider Buying and Selling at Krystal Biotech

In related news, Director Dino Rossi sold 25,000 shares of the stock in a transaction on Friday, August 14th. The shares were sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the transaction, the director owned 50,000 shares of the company’s stock, valued at approximately $16,456,000. This trade represents a 33.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Friday, September 4th. The stock was sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the completion of the transaction, the insider owned 1,302,145 shares in the company, valued at approximately $467,886,741.40. The trade was a 1.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Krystal Biotech

A number of large investors have recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in Krystal Biotech during the 2nd quarter valued at about $1,554,113,000. William Blair Investment Management LLC bought a new position in Krystal Biotech during the 2nd quarter valued at approximately $211,909,000. Jupiter Topco LLC purchased a new stake in Krystal Biotech in the 2nd quarter worth approximately $95,387,000. Bank of America Corp DE purchased a new stake in Krystal Biotech in the 2nd quarter worth approximately $95,308,000. Finally, Bank of New York Mellon Corp purchased a new stake in Krystal Biotech in the 2nd quarter worth approximately $60,809,000. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company uses engineered herpes simplex virus type 1 (HSV-1) vectors designed to deliver functional genes to targeted tissues, with the goal of treating diseases caused by genetic mutations.

Krystal Biotech’s lead product, VYJUVEK (beremagene geperpavec-svdt), is a topical gene therapy approved in the United States for the treatment of wounds in patients with dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and recurrent blistering.